Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
Hamauchi S, Yasui H, Yokota T, Tsushima T, Fushiki K, Naito T, Ono A, Kado N, Onozawa Y, Murakami H, Takahashi T, Hirashima Y, Mori K, Yamazaki K. Hamauchi S, et al. Among authors: yamazaki k. Invest New Drugs. 2024 Dec;42(6):655-663. doi: 10.1007/s10637-024-01480-w. Epub 2024 Oct 26. Invest New Drugs. 2024. PMID: 39460855 Clinical Trial.
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H. Yoshino T, et al. Among authors: yamazaki k. Jpn J Clin Oncol. 2007 Sep;37(9):686-91. doi: 10.1093/jjco/hym091. Epub 2007 Aug 24. Jpn J Clin Oncol. 2007. PMID: 17720736
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Taira K, Boku N, Fukutomi A, Onozawa Y, Hironaka S, Yoshino T, Yasui H, Yamazaki K, Taku K, Hashimoto T, Nishimura T. Taira K, et al. Among authors: yamazaki k. J Gastroenterol. 2008;43(11):875-80. doi: 10.1007/s00535-008-2236-z. Epub 2008 Nov 18. J Gastroenterol. 2008. PMID: 19012041
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E. Yamamoto N, et al. Among authors: yamazaki k. Cancer Chemother Pharmacol. 2009 Nov;64(6):1165-72. doi: 10.1007/s00280-009-0979-8. Epub 2009 Mar 24. Cancer Chemother Pharmacol. 2009. PMID: 19308410 Clinical Trial.
3,354 results